治疗和管理慢性乙型肝炎病毒感染的先进治疗方法，疫苗接

StephenW

Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?
Ganesh Selvaraj Duraisamy  1 , Dattatry Bhosale  1 , Ivana Lipenská  1 , Ivana Huvarova  1 , Daniel Růžek  1   2 , Marc P Windisch  3   4 , Andrew D Miller  1   5   6
Affiliations
Affiliations

    1
    Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
    2
    Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 České Budějovice, Czech Republic.
    3
    Applied Molecular Virology Laboratory, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea.
    4
    Division of Bio-Medical Science and Technology, University of Science and Technology, Daejeon 305-350, Korea.
    5
    Department of Chemistry and Biochemistry, Mendel University in Brno, Zemědělská 1, Černá Pole, CZ-61300 Brno, Czech Republic.
    6
    KP Therapeutics (Europe) s.r.o., Purkyňova 649/127, CZ-61200 Brno, Czech Republic.

    PMID: 32906840 DOI: 10.3390/v12090998

Abstract

The management of chronic hepatitis B virus (CHB) infection is an area of massive unmet clinical need worldwide. In spite of the development of powerful nucleoside/nucleotide analogue (NUC) drugs, and the widespread use of immune stimulators such as interferon-alpha (IFNα) or PEGylated interferon-alpha (PEG-IFNα), substantial improvements in CHB standards of care are still required. We believe that the future for CHB treatment now rests with advanced therapeutics, vaccination, and precision medicine, if all are to bring under control this most resilient of virus infections. In spite of a plethora of active drug treatments, anti-viral vaccinations and diagnostic techniques, the management of CHB infection remains unresolved. The reason for this is the very complexity of the virus replication cycle itself, giving rise to multiple potential targets for therapeutic intervention some of which remain very intractable indeed. Our review is focused on discussing the potential impact that advanced therapeutics, vaccinations and precision medicine could have on the future management of CHB infection. We demonstrate that advanced therapeutic approaches for the treatment of CHB, in the form of gene and immune therapies, together with modern vaccination strategies, are now emerging rapidly to tackle the limitations of current therapeutic approaches to CHB treatment in clinic. In addition, precision medicine approaches are now gathering pace too, starting with personalized medicine. On the basis of this, we argue that the time has now come to accelerate the design and creation of precision therapeutic approaches (PTAs) for CHB treatment that are based on advanced diagnostic tools and nanomedicine, and which could maximize CHB disease detection, treatment, and monitoring in ways that could genuinely eliminate CHB infection altogether.

Keywords: RNA interference; active pharmaceutical ingredient; biophysics; hepatitis B virus; lipid-based nanoparticles; nanomedicine; nanotechnology; personalized medicine; plasmid DNA; precision medicine; precision therapeutics approach; small interfering RNA.

StephenW

治疗和管理慢性乙型肝炎病毒感染的先进治疗方法，疫苗接种和精密医学；我们在哪里，我们要去哪里？
Ganesh Selvaraj Duraisamy 1，Dattatry Bhosale 1，IvanaLipenská1，Ivana Huvarova 1，DanielRůžek1 2，Marc P Windisch 3 4，Andrew D Miller 1 5 6
隶属关系
隶属关系

    1个
    兽医研究所，捷克共和国布尔诺CZ-62100，胡德科娃70号。
    2
    捷克科学院生物中心寄生虫研究所，Branisovska 31，CZ-37005捷克布杰约维采。
    3
    巴斯德研究所应用分子病毒学实验室，韩国京畿道城南市盆唐区三平洞696号，韩国463-400。
    4
    科技大学生物医学科学技术系，韩国大田305-350。
    5
    布尔诺的孟德尔大学化学与生物化学系，捷克共和国布尔诺CZ-61300ČernáPole的Zemědělská1。
    6
    KP Therapeutics（Europe）s.r.o.，Purkyňova649/127，CZ-61200布尔诺，捷克共和国。

    PMID：32906840 DOI：10.3390 / v12090998

抽象

慢性乙型肝炎病毒（CHB）感染的管理是全球范围内大量未满足的临床需求的领域。尽管开发了强大的核苷/核苷酸类似物（NUC）药物，并且广泛使用了免疫刺激剂，例如干扰素-α（IFNα）或聚乙二醇化干扰素-α（PEG-IFNα），但CHB护理标准仍得到了实质性改善。仍然需要。我们相信，如果要控制住这种最具抵抗力的病毒感染，CHB治疗的未来将取决于先进的治疗方法，疫苗接种和精密药物。尽管有大量的活性药物治疗，抗病毒疫苗和诊断技术，CHB感染的管理仍未解决。其原因是病毒复制周期本身非常复杂，从而产生了许多潜在的治疗干预靶标，其中一些确实确实非常棘手。我们的审查重点是讨论先进的治疗方法，疫苗接种和精密药物可能对CHB感染的未来管理产生潜在影响。我们证明，以基因和免疫疗法的形式来治疗CHB的先进治疗方法，以及现代疫苗接种策略，正在迅速出现，以解决当前临床上CHB治疗的治疗方法的局限性。此外，从个性化医学开始，精确医学方法也在不断发展。基于此，我们认为现在是时候加速设计和创建基于先进诊断工具和纳米药物的CHB治疗精密治疗方法（PTA）了，该方法可以最大程度地检测，治疗CHB疾病，并以能够彻底消除CHB感染的方式进行监控。

关键词：RNA干扰；活性药物成分；生物物理学乙型肝炎病毒;基于脂质的纳米颗粒；纳米医学纳米技术个性化医学；质粒DNA；精密医学精密治疗方法；小干扰RNA。

StephenW

https://www.mdpi.com/1999-4915/12/9/998/pdf